This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) (HCQ)

This study is ongoing, but not recruiting participants.
Cancer Research UK
Information provided by (Responsible Party):
University College, London Identifier:
First received: May 8, 2012
Last updated: November 7, 2016
Last verified: November 2016

There is emerging evidence that hydroxychloroquine (HCQ), a drug used commonly in the prevention/ treatment of malaria, rheumatoid arthritis and lupus erythematosus, may improve survival outcome in a variety of cancers including HGG, with few side effects.

In this trial the investigators wish to investigate whether treatment with radiotherapy and hydroxychloroquine is more effective than treatment with radiotherapy alone.

Condition Intervention Phase
Glioblastoma Drug: Hydroxychloroquine Radiation: Radiotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

Resource links provided by NLM:

Further study details as provided by University College, London:

Primary Outcome Measures:
  • 1 year Survival [ Time Frame: The survival rate will be calculated by the number of patients alive 1 year after entering the trial. ]
    The primary endpoint of the trial is survival at one year

Secondary Outcome Measures:
  • Toxicity [ Time Frame: Toxicity will be assessed during and up to 30 days after treatment ]
    Adverse Events will be collected for all patients in the trial during treatment and up to 30 days afterwards.

Enrollment: 54
Study Start Date: May 2013
Estimated Study Completion Date: October 2017
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm B
Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
Drug: Hydroxychloroquine
200mg bd from 14 days post surgery until clinical or radiological progression
Other Name: HCQ
Active Comparator: Arm A: SCRT alone
Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
Radiation: Radiotherapy
Short Course radiotherapy


Ages Eligible for Study:   70 Years to 100 Years   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients aged ≥70 yrs identified through the neurooncology MDT.
  • A histological diagnosis of HGG, either from biopsy or resection.
  • A life expectancy of > 2 months
  • An ECOG performance status of 0/1
  • Absolute neutrophil count ≥ 1.5 x 109
  • Platelet count ≥ 100 x 109
  • Bilirubin ≤ 1.5 mg/dL (or ≤ 25.6 µmol/L)
  • Creatinine ≤ 2 times upper limit of normal (ULN)
  • ALT and AST ≤ 4 times ULN
  • Mini Mental Status Exam score ≥ 17 (Appendix 10)
  • Written informed consent
  • Ready to start radiotherapy within 4 weeks of surgery

Exclusion Criteria:

  • Concurrent psoriasis unless the disease is well controlled and patient is under the care of a specialist for the disorder who agrees to monitor for exacerbations
  • Prior macular degeneration or diabetic retinopathy
  • Concurrent serious infection or medical illness that would preclude study therapy
  • Another malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin
  • Porphyria
  • Glucose- 6 phosphate dehydrogenase (G6PD) deficiency
  • Alcoholic liver disease
  • Any other concurrent severe/uncontrolled medical conditions
  • Currently taking amiodarone
  • Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell therapy, or gene therapy), or hormonal therapy for brain tumour
  • Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite® brachytherapy
  • Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine)
  • Other concurrent chemotherapeutic or investigational agents for this cancer (Concurrent glucocorticoids will be allowed
  • Documented side effects to chloroquine or related agents.
  • Unable to give informed consent
  • Patients with a history of a psychological illness or condition that in the opinion of the investigator may adversely affect compliance with study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01602588

United Kingdom
St James's University Hospital
Leeds, West Yorkshire, United Kingdom, LS9 7TF
Glan Clwyd Hospital
Bodelwyddan, United Kingdom, LL18 5UJ
Addenbrooke's Hospital
Cambridge, United Kingdom, CB2 0QQ
Ninewells Hospital
Dundee, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Royal Surrey County Hospital
Guildford, United Kingdom, GU2 7XX
University College Hospital
London, United Kingdom, NW1 2BU
Guy's and St Thomas's Hospitals
London, United Kingdom, SE1 9RT
Charing Cross Hospital
London, United Kingdom, w6 8RF
Christie Hospital
Manchester, United Kingdom, M20 4BX
James Cook University Hospital
Middlesbrough, United Kingdom, TS4 3BW
Freeman Hospital
Newcastle, United Kingdom, NE7 7DN
Norfolk & Norwich University Hospitals
Norwich, United Kingdom, NR4 7UY
The Royal Preston Hospital
Preston, United Kingdom, PR2 9HT
Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom, ST4 6QG
Sponsors and Collaborators
University College, London
Cancer Research UK
Principal Investigator: Susan Short, Professor St James's University Hospital
  More Information

Responsible Party: University College, London Identifier: NCT01602588     History of Changes
Other Study ID Numbers: UCL11/0404
Study First Received: May 8, 2012
Last Updated: November 7, 2016

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents processed this record on June 23, 2017